The Inaccuracy of Patient Recall for COPD Exacerbation Rate Estimation and Its Implications: Results from Central Adjudication.

[1]  M. Puhan,et al.  Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. , 2014, Journal of clinical epidemiology.

[2]  David R. Gagnon,et al.  Daily Step Count Predicts Acute Exacerbations in a US Cohort with COPD , 2013, PloS one.

[3]  M. Puhan,et al.  Simple functional performance tests and mortality in COPD , 2013, European Respiratory Journal.

[4]  Mark Woodward,et al.  Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial , 2013, PloS one.

[5]  Dacheng Liu,et al.  Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. , 2012, Respiratory medicine.

[6]  W. Xiong,et al.  Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis , 2012, Journal of clinical pharmacy and therapeutics.

[7]  M. Puhan,et al.  Characteristics of Dutch and Swiss primary care COPD patients – baseline data of the ICE COLD ERIC study , 2011, Clinical epidemiology.

[8]  A. Schrijvers,et al.  The impact of using different symptom-based exacerbation algorithms in patients with COPD , 2011, European Respiratory Journal.

[9]  N. Leidy,et al.  Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. , 2011, American journal of respiratory and critical care medicine.

[10]  Dirkje S Postma,et al.  Definitions of exacerbations: does it really matter in clinical trials on COPD? , 2009, Chest.

[11]  S. Yusuf,et al.  Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs , 2009, Clinical trials.

[12]  M. Woodward,et al.  Effects of the End Point Adjudication Process on the Results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) , 2009, Stroke.

[13]  Gerben ter Riet,et al.  BMC Pulmonary Medicine BioMed Central Study protocol Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCT , 2009 .

[14]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[15]  M Cazzola,et al.  Outcomes for COPD pharmacological trials: From lung function to biomarkers. , 2008, Revista portuguesa de pneumologia.

[16]  F. Maltais,et al.  Counting, analysing and reporting exacerbations of COPD in randomised controlled trials , 2007, Thorax.

[17]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[18]  Robert A Wise,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[19]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[20]  M. Martínez-García,et al.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.

[21]  C. Kooperberg,et al.  Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. , 2004, American journal of epidemiology.

[22]  H. Schünemann,et al.  Measurement of agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians--a prospective study. , 2004, Respiratory medicine.

[23]  A. Pont,et al.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.

[24]  G. Guyatt,et al.  Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. , 2003, Journal of clinical epidemiology.

[25]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[26]  R. Califf,et al.  Systematic adjudication of myocardial infarction end-points in an international clinical trial , 2001, Current controlled trials in cardiovascular medicine.

[27]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[28]  M Dosemeci,et al.  Non-differential misclassification and bias towards the null: a clarification. , 1995, Occupational and environmental medicine.

[29]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[30]  G. Huston.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[31]  C Brownie,et al.  The effects of exposure misclassification on estimates of relative risk. , 1986, American journal of epidemiology.